Vimarsana
Biggest News Aggregation in the World

Page 6 - Colitis Organization News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Colitis Organization. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Colitis Organization Today - Breaking & Trending Today

Switching Study Concludes That Transition From Humira To Samsung Bioepis's Adalimumab Biosimilar Is Safe and Effective | Goodwin - Vimarsana News

Switching Study Concludes That Transition From Humira To Samsung Bioepis's Adalimumab Biosimilar Is Safe and Effective | Goodwin

Results of the PROPER study, an interim analysis assessing the safety and efficacy of switching from Abbvie’s Humira to Samsung Bioepsis’s biosimilar adalimumab product, SB5, were...

Immunic, Inc. Reports Year End 2021 Financial Results and Highlights Recent Activity - Vimarsana News

Immunic, Inc. Reports Year End 2021 Financial Results and Highlights Recent Activity

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused...

DGAP-News: Immunic, Inc.: Immunic to Present Preclinical Data for Vidofludimus Calcium at the 17th Congress of ECCO and Announces Blinded Baseline Characteristics of Phase 2 Trial of Vidofludimus Calcium in Ulcerative Colitis - Vimarsana News

DGAP-News: Immunic, Inc.: Immunic to Present Preclinical Data for Vidofludimus Calcium at the 17th Congress of ECCO and Announces Blinded Baseline Characteristics of Phase 2 Trial of Vidofludimus Calcium in Ulcerative Colitis

DGAP-News: Immunic, Inc. / Key word(s): Conference/Study results Immunic to Present Preclinical Data for Vidofludimus Calcium at the 17th Congress of ECCO and Announces Blinded Baseline Characteristics

Herbal Products for IBS; Liver Transplant, Diabetes, and Cancer; IBD Work Impairment - Vimarsana News

Herbal Products for IBS; Liver Transplant, Diabetes, and Cancer; IBD Work Impairment

News and commentary from the world of gastroenterology and hepatology

Second Genome Nominates Development Candidate Targeting PAI-1/2 for the Treatment of Inflammatory Bowel Disease (IBD) - Vimarsana News

Second Genome Nominates Development Candidate Targeting PAI-1/2 for the Treatment of Inflammatory Bowel Disease (IBD)

/PRNewswire/ -- Second Genome, a biotechnology company that leverages its proprietary platform to discover and develop precision therapies and biomarkers,...